Nature: Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label ...
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label ...
The gene that causes cystic fibrosis may persist in human populations because, although two copies of it kill, having just one copy protects against tuberculosis, researchers say. Researchers at Yale ...
Elexacaftor–ivacaftor–tezacaftor therapy is efficacious in cystic fibrosis among patients with at least one copy of the Phe508del allele. In this trial involving patients with either a gating or ...
The New England Journal of Medicine: Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Atypical cystic fibrosis is a mild form of cystic fibrosis. People with this type of cystic fibrosis can experience symptoms that come and go or that are less severe than those people with classic ...
USA Today: Everything to know about cystic fibrosis and what causes it
Morning Overview on MSN: Gene therapy targets rare cystic fibrosis mutation affecting ~10%
For roughly one in ten people living with cystic fibrosis, the drugs that have transformed survival for most CF patients are useless. These individuals carry what scientists call a nonsense mutation ...
Healthline: What Is Autosomal Recessive Cystic Fibrosis, and Who Does It Affect?
Cystic fibrosis (CF) is an autosomal recessive condition. This means that a person will have CF only if they receive the affected gene from both parents at conception. Share on Pinterest Dalibor ...